HD-OPM Archive
Topics › Plaque, CAC & CT angiography

Six statin trials show 5 to 17% total plaque reversal, with the best results at lowest LDL

Louis Nervegna · Oct 31, 2026 · ♥ 12 reactions · 0 comments · original Facebook post
Plaque, CAC & CT angiographyStatinsLDL, ApoB & lipid panel
AI summary & key facts

Louis shares a chart of randomized trials showing plaque reversal with statins, ezetimibe and PCSK9 inhibitors, with total atheroma volume change plotted against LDL-C. Total plaque reversal ranged from about 5% to 17% in six older statin trials, measured by CT angiography or IVUS, and came from soft rather than calcified plaque. The chart suggests total plaque reversal begins once LDL falls below roughly 90 mg/dL.

SIX older randomized trials have shown reversal of total plaque (TAV) with statins
(If we count very recent trials, it is even more. For example, the FLOWPROMOTE trial: facebook.com/share/v/1My2cZxnm7.)

The reversals in total plaque have ranged anywhere from 5% to 17%.

I listed each of the trials by name below, and the amount of the reversal:

COSMOS ~5%

SATURN ~5.5%

ASTEROID ~6.5%

IBIS-4 ~7.5%

STABLE ~8%

JAPAN-ACS ~17%

(FLOWPROMOTE ~14%)

The reversals were proven with either CT-angiogram or IVUS (the gold standard).

Note that these reversals in total plaque were a result of reversing soft plaque, not calcified plaque.

The reality is that plaque reversal with statins is fairly common in the first few years after starting. You can read the many past posts about this by searching the group for the tag #statinreverseHD.

Research cited

Statins, ezetimibe, and PCSK9 inhibitors reverse soft plaque and reduce total plaque.

A summary of all the major randomized controlled trials showing plaque reversal, using:

The x-axis is LDL cholesterol in units of mmol/L. (Multiply by 40 to convert to mg/dL.)

The y-axis is decrease in Total Atheroma Volume (TAV) in percent. This is a measure of total plaque volume.

Reference:

Paper · Journal of the American College of Cardiology · 2022Coronary Atherosclerotic Plaque Regressionjacc.org

The chart shows that it is possible to start seeing reversal of total plaque volume (TAV) with medication once the LDL-C starts getting below roughly 90mg/dL.

The best result achieved with medication was using statins in the Japan-ACS trial. This lead to a massive 17% reduction in total atheroma volume (TAV) in patients with acute coronary syndrome. The dose used was 20mg atorvastatin or 4mg pitavastatin.

↪ Japan-ACS: pitavastatin and atorvastatin both regressed coronary plaque by about 17-18%

Paper · Journal of the American College of Cardiology · 2009Effect of Intensive Statin Therapy on Regression of Coronary Atherosclerosis in Patients With Acute Coronary Syndromejacc.org

The 6 trials with statins on this chart showing plaque reversal are one of the major reasons why they remain standard of care in high risk patients.

Total atheroma volume (TAV) refers to the overall volume of plaque buildup within the coronary arteries or within a particular set of lesions that are being studied. It is a measure of the total plaque burden, and is assessed in these studies using accurate imaging techniques like intravascular ultrasound (IVUS) or coronary computed tomography angiography (CCTA). TAV includes all types of plaque, both calcified and soft plaque.

The graph shows the change in the total atheroma (plaque) volume compared to baseline. For example, a 6.5% reduction in TAV would mean that the total plaque volume in the area being measured by IVUS or CT-angiogram is now 6.5% smaller than it was at baseline.

You can see past posts in the group on the topic of reversing plaque by searching for the tag #reverseHD.

#reverseHD #statinrctsHD #statinsHD #ezetimibeHD #pcsk9HD #tavHD #pavHD #ivusHD #ctaHD #statinreverseHD #japanacsHD #pcsk9reverseHD #ezetimibereverseHD

No photo description available.
← newer: Psyllium lowers LDL about 13 mg/dL across 28 trials by trappolder: No randomized trial shows ezetimibe alone lowers heart attac →